Literature DB >> 25553077

The role and utility of faecal markers in inflammatory bowel disease.

Frank S Lehmann1, Emanuel Burri1, Christoph Beglinger2.   

Abstract

Crohn's disease and ulcerative colitis are characterized by periods of symptomatic relapse and remission. Diagnosis and assessment of inflammatory bowel disease has so far been based on clinical evaluation, serum parameters, radiology and endoscopy. Faecal markers such as calprotectin or lactoferrin have emerged as new diagnostic tools to detect and monitor intestinal inflammation. This review focuses on their potential clinical applications and limitations in the management of inflammatory bowel disease.

Entities:  

Keywords:  Crohn’s disease; calprotectin; inflammation; inflammatory bowel disease; lactoferrin; ulcerative colitis

Year:  2015        PMID： 25553077      PMCID： PMC4265086          DOI： 10.1177/1756283X14553384

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN： 1756-283X            Impact factor:   4.409


  110 in total

1.  Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study.

Authors:  Liselotte Kok; Sjoerd G Elias; Ben J M Witteman; Jelle G Goedhard; Jean W M Muris; Karel G M Moons; Niek J de Wit
Journal:  Clin Chem       Date:  2012-03-09       Impact factor: 8.327

2.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

3.  Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease.

Authors:  Elzbieta Czub; Karl-Heinz Herzig; Anna Szaflarska-Popawska; Karlheinz Kiehne; Piotr Socha; Halina Woś; Barbara Kamińska; Michał Błaszczyński; Wojciech Cichy; Grazyna Bała; Jacek Brodzicki; Urszula Grzybowska-Chlebowczyk; Jarosław Walkowiak
Journal:  Scand J Gastroenterol       Date:  2007-10       Impact factor: 2.423

4.  Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin.

Authors:  M Steinbakk; C F Naess-Andresen; E Lingaas; I Dale; P Brandtzaeg; M K Fagerhol
Journal:  Lancet       Date:  1990-09-29       Impact factor: 79.321

5.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease.

Authors:  M D Baugh; M J Perry; A P Hollander; D R Davies; S S Cross; A J Lobo; C J Taylor; G S Evans
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

6.  Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.

Authors:  Kaija-Leena Kolho; Taneli Raivio; Harry Lindahl; Erkki Savilahti
Journal:  Scand J Gastroenterol       Date:  2006-06       Impact factor: 2.423

Review 7.  Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.

Authors:  Emanuel Burri; Christoph Beglinger
Journal:  Swiss Med Wkly       Date:  2012-04-05       Impact factor: 2.193

8.  Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

Authors:  G T Ho; H M Lee; G Brydon; T Ting; N Hare; H Drummond; A G Shand; D C Bartolo; R G Wilson; M G Dunlop; I D Arnott; J Satsangi
Journal:  Am J Gastroenterol       Date:  2009-02-17       Impact factor: 10.864

9.  Fecal lactoferrin: a new parameter to monitor infliximab therapy.

Authors:  Stephan Buderus; James Boone; David Lyerly; Michael J Lentze
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

10.  Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study.

Authors:  Michael Manz; Emanuel Burri; Claude Rothen; Nuschin Tchanguizi; Christian Niederberger; Livio Rossi; Christoph Beglinger; Frank Serge Lehmann
Journal:  BMC Gastroenterol       Date:  2012-01-10       Impact factor: 3.067
View more
  38 in total

1.  Current Use of Fecal Calprotectin in the Management of Patients With Inflammatory Bowel Disease.

Authors:  Marc Ferrante
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-02

2.  Association of enteric parasitic infections with intestinal inflammation and permeability in asymptomatic infants of São Tomé Island.

Authors:  Marisol Garzón; Luis Pereira-da-Silva; Jorge Seixas; Ana Luísa Papoila; Marta Alves; Filipa Ferreira; Ana Reis
Journal:  Pathog Glob Health       Date:  2017-03-10       Impact factor: 2.894

Review 3.  Role of high-mobility group box 1 protein in inflammatory bowel disease.

Authors:  Zhen Hu; Xiaoyun Wang; Lei Gong; Gaojue Wu; Xiaobin Peng; Xuejun Tang
Journal:  Inflamm Res       Date:  2015-06-16       Impact factor: 4.575

Review 4.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

5.  Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission.

Authors:  Takahiro Miyazu; Natsuki Ishida; Ryosuke Takano; Satoshi Tamura; Mihoko Yamade; Yasushi Hamaya; Shinya Tani; Moriya Iwaizumi; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

6.  Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.

Authors:  Marisa Iborra; Julia Herreras; Marta Maia Boscá-Watts; Xavier Cortés; Galo Trejo; Elena Cerrillo; David Hervás; Miguel Mínguez; Belén Beltrán; Pilar Nos
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

Review 7.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

8.  Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies.

Authors:  Tue Bjerg Bennike; Thomas Gelsing Carlsen; Torkell Ellingsen; Ole Kristian Bonderup; Henning Glerup; Martin Bøgsted; Gunna Christiansen; Svend Birkelund; Allan Stensballe; Vibeke Andersen
Journal:  Inflamm Bowel Dis       Date:  2015-09       Impact factor: 5.325

9.  Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.

Authors:  Rahul Kalla; Nicholas A Kennedy; Nicholas T Ventham; Ray K Boyapati; Alex T Adams; Elaine R Nimmo; Micaela R Visconti; Hazel Drummond; Gwo-Tzer Ho; Rebecca J Pattenden; David C Wilson; Jack Satsangi
Journal:  Am J Gastroenterol       Date:  2016-09-06       Impact factor: 12.045

10.  Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results.

Authors:  Axel Dignass; Ayesha Akbar; Ailsa Hart; Sreedhar Subramanian; Gilles Bommelaer; Daniel C Baumgart; Jean-Charles Grimaud; Guillaume Cadiot; Richard Makins; Syed Hoque; Guillaume Bouguen; Bruno Bonaz
Journal:  J Crohns Colitis       Date:  2016-01-27       Impact factor: 9.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.